First-line therapy for ovarian carcinoma: What's next?

Cancer Investigation

Volumn 22, Issue SUPPL. 2, 2004, Pages 21-28

  Thigpen, Tate ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Ovarian carcinoma; Paclitaxel

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEFITINIB; GEMCITABINE; INTERFERON; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; VALSPODAR; VASCULOTROPIN INHIBITOR;

ADJUVANT THERAPY; ADVANCED CANCER; ASCITES FLUID CYTOLOGY; CANCER STAGING; CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESPONSE; EARLY DIAGNOSIS; FEMALE; HIGH RISK PATIENT; HUMAN; MAINTENANCE THERAPY; OVARY CARCINOMA; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; RISK FACTOR; SCREENING TEST; SURGICAL TECHNIQUE; SURVIVAL TIME; TRANSVAGINAL ECHOGRAPHY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 11244304530     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200030115     Document Type: Conference Paper

References (25)

1. van der Burg, M.E.L.; van Lent, M.; Buyse, M.; et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N. Eng. J. Med. 1995, 332, 629.
2. Rose, P.; Nerenstone, S.; Brady, M.; et al. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group Study. Proc. Am. Soc. Clin. Oncol. 2002, 21, 201 (abstr).
3. McGuire, W.P.; Hoskins, W.J.; Brady, M.F.; et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Eng. J. Med. 1996, 334, 1-6.
4. Piccart, M.J.; Bertelsen, K.; James, K.; et al. Randomized intergroup trial of cisplatin-paclitaxel vs. cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 2000, 92, 699-708.
5. Pertussini, E.; Ratajczak, J.; Majka, M.; et al. Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood 2001, 97, 638-644.
6. du Bois, A.; Luck, H.-J.; Meier, W.; et al. A randomized clinical trial of cisplatin/paclitaxel vs. carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 2003, 95, 1320-1330.
7. Ozols, R.; Bundy, B.; Greer, B.; et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2003, 21, 3194-3200.
8. Alberts, D.S.; Liu, P.Y.; Hannigan, E.V.; et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide vs. intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Eng. J. Med. 1996, 335, 1950-1955.
9. Markman, M.; Bundy, B.; Alberts, D.; et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel vs. moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 2001, 19, 1001-1007.
10. Armstrong, D.; Bundy, B.; Baergen, R.; et al. Randomized phase III study of intravenous paclitaxel and cisplatin vs. intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group Trial (GOG 172). Proc. Am. Soc. Clin. Oncol. 2002, 21, 201a.
11. Vasey, P. Preliminary results of the SCOTROC trial: a phase III comparison of paclitaxelcarboplatin and docetaxel-carboplatin a first-line chemotherapy for stage IC-IV epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 2001, 20, 202a (abstr).
12. du Bois, A.; Weber, B.; Pfisterer, J.; et al. Epirubicin/paclitaxel/ carboplatin vs. paclitaxel/ carboplatin in first-line treatment of ovarian cancer FIGO stages UB-IV. Interim results of an AGO-GINECO intergroup phase III trial. Proc. Am. Soc. Clin. Oncol. 2001, 20, 202a (abstr).
13. Kristensen, G.; Vergoe, I.; Stuart, G.; et al. First line treatment of ovarian cancer FIGO stagees IIB-IV with paclitaxel/epirubicin/carboplatin vs. paclitaxel/carboplatin. Interim results of an NSGO-EORTC-NCIC CTG Gynecologic Cancer Intergroup phase III trial. Proc. Am. Soc. Clin. Oncol. 2002, 21, 202a (abstr).
14. Bookman, M.; Darcy, K.; Clarke-Pearson, D.; et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 2003, 21, 283-290.
15. Joly, F.; Mangioni, C.; Nicolleto, M.; et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin vs. paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 2002, 21, 202a (abstr).
16. Windbichler, G.; Hausmaninger, H.; Stummvoll, W.; et al. Interferon-γ in the first-line therapy of ovarian cancer: a randomized phase III trial. Br. J. Cancer 2000, 82, 1138-1144.
17. Ozols, R. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J. Clin. Oncol. 2003, 21, 2451-2453.
18. Pignata, S.; Deplacido, S.; Scambia, G.; et al. Topotecan vs. nihil after response to carboplatin and paclitaxel in advanced ovarian cancer. Early results of the MITO-1 study. Proc. Am. Soc. Clin. Oncol. 2003, 22, 446 (abstr).
19. Pfisterer, J.; Lotholary, A.; Kimmig, R.; et al. Paclitaxel/carboplatin vs. paclitaxel/carboplatin followed by topotecan in first-line treatment of ovarian cancer FIGO stages IIB-IV. Interim results of a gynecologic cancer intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO. Proc. Am. Soc. Clin. Oncol. 2003, 22, 446. (abstr).
20. Markman, M.; Liu, P.; Wilczynski, S.; et al. Phase III randomized trial of 12 vs. 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 2003, 21, 2460-2465.
21. Browder, T.; Butterfield, C.; Kraling, B.; et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2001, 60, 1878-1886.
22. Day, T.G.; Smith, J.P. Diagnosis and staging of ovarian carcinoma. Semin. Oncol. 1975, 2, 217.
23. Young, R.C.; Walton, L.; Ellenberg, S.S.; et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med. 1990, 322, 1021-1027.
24. ICON and ACTION Collaborators: International collaborative ovarian neoplasm trial I and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J. Natl. Cancer Inst. 2003, 95, 105-112.
25. Bell, J.; Brady, M.; Lage, J.; et al. A randomized phase III trial of three vs. six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a Gynecologic Oncology Group Study. Gynec. Oncol. 2003, 88, 156 (abstr).